Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
Edgewise Therapeutics (EWTX) Stock Price & Analysis
112 Followers
EWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.12 - $20.69
Previous Close$15.65
Volume526.41K
Average Volume (3M)752.37K
Market Cap
$1.46B
Enterprise Value$1.15B
Total Cash (Recent Filing)$318.39M
Total Debt (Recent Filing)$5.41M
Price to Earnings (P/E)-10.0
Beta1.07
Next Earnings
May 09, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding93,110,623
10 Day Avg. Volume487,066
30 Day Avg. Volume752,366
Standard Deviation0.23
R-Squared0.00112
Alpha0.00371
Financial Highlights & Ratios
Price to Book (P/B)4.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-19.37
Forecast
1Y Price Target
$35.33Price Target Upside119.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Edgewise Therapeutics News
Ownership Overview
43.49% Insiders
13.10% Mutual Funds
8.26% Other Institutional Investors
35.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $5.12 and its highest was $20.69 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Currently, no data Available
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 14 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Feb 22, 2024. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.035.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -$0.39.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 93,410,480 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went down -0.743%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Among the largest hedge funds holding Edgewise Therapeutics’s share is Viking Global Investors LP. It holds Edgewise Therapeutics’s shares valued at 67M.
---
Edgewise Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.33 (119.30% Upside)
$35.33 (119.30% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.38%
12-Months-Change
Fundamentals
Return on Equity
-30.10%
Trailing 12-Months
Asset Growth
-7.37%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
---
EWTX Stock 12 Months Forecast
Average Price Target
$35.33
▲(119.30% Upside)
Technical Analysis
Best Analysts Covering EWTX
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+39.61%
reiterated a buy rating 10 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +39.61% per trade.
---